Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 7INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 767Lymphoma 713Leukemia, Lymphocytic, Chronic, B-Cell 560Lymphoma, Follicular 515Lymphoma, Large B-Cell, Diffuse 440Precursor Cell Lymphoblastic Leukemia-Lymphoma 331Recurrence 317Lymphoma, B-Cell 294Neoplasms 261Lymphoma, Mantle-Cell 251Leukemia 231Multiple Myeloma 189Hodgkin Disease 179Leukemia, Myeloid, Acute 178Lymphoma, B-Cell, Marginal Zone 135Lymphoma, T-Cell, Peripheral 119Burkitt Lymphoma 105Myelodysplastic Syndromes 101Hematologic Neoplasms 100Lymphoma, T-Cell, Cutaneous 88Waldenstrom Macroglobulinemia 84Leukemia, B-Cell 79Lymphoma, T-Cell 74Leukemia, Myelogenous, Chronic, BCR-ABL Positive 65Lymphoproliferative Disorders 57Hematologic Diseases 57Melanoma 54Carcinoma, Non-Small-Cell Lung 54Breast Neoplasms 51Mycosis Fungoides 49

Interventions

Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphomatoid Papulosis × Lymphoid × Clear all
NCT00099255 2014-12-18

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

Seagen Inc.

Phase 2 Completed
40 enrolled
DermatologicLymphoidSarcoma

Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡